If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Insulin Efsitora Alfa
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling.
When will insulin efsitora alfa become available?
Lilly plans to submit efsitora for people with T2D in the US, EU, and Japan in 2025.
Availability of Insulin Efsitora
Insulin efsitora alfa is a once-weekly basal insulin currently being investigated for the treatment of patients with diabetes.1
Lilly plans to submit efsitora for people with T2D in the US, EU, and Japan in 2025.2
Lilly has concluded that the benefit risk of efsitora is different in people with T2D compared to people with T1D. At this time, Lilly has no plans to study efsitora further in people with T1D.
Lilly’s autoinjector was used to administer fixed doses of efsitora in QWINT-1. Throughout the QWINT trials, efsitora was also administered using the Kwikpen, and we will continue to assess device options for commercialization. Lilly is excited about the potential to simplify insulin treatment for people with type 2 diabetes through a fixed-dose regimen similar to the well-established and accepted method of starting and titrating weekly incretin products.
References
1Bergenstal RM, Philis-Tsimikas A, Wysham C, et al. Once-weekly insulin efsitora alfa: design and rationale for the QWINT phase 3 clinical development programme. Diabetes Obes Metab. 2024;26(8):3020-3030. https://doi.org/10.1111/dom.15604
2Q4 2024 Earnings Call. Eli Lilly and Company February 6, 2025 Q4 2024 Lilly Presentation. Accessed February 24, 2025. https://investor.lilly.com/static-files/09d156c0-f88d-420b-b5f1-1ed2b417461b
Date of Last Review: July 16, 2025